| References: |
Azeliragon（PF-04494700,TTP488） is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).
TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.
in vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d. Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.For the detailed information of Azeliragon（PF-04494700,TTP488）, the solubility of Azeliragon（PF-04494700,TTP488） in water, the solubility of Azeliragon（PF-04494700,TTP488） in DMSO, the solubility of Azeliragon（PF-04494700,TTP488） in PBS buffer, the animal experiment (test) of Azeliragon（PF-04494700,TTP488）, the cell expriment (test) of Azeliragon（PF-04494700,TTP488）, the in vivo, in vitro and clinical trial test of Azeliragon（PF-04494700,TTP488）, the EC50, IC50,and affinity,of Azeliragon（PF-04494700,TTP488）, For the detailed information of Azeliragon（PF-04494700,TTP488）, the solubility of Azeliragon（PF-04494700,TTP488） in water, the solubility of Azeliragon（PF-04494700,TTP488） in DMSO, the solubility of Azeliragon（PF-04494700,TTP488） in PBS buffer, the animal experiment (test) of Azeliragon（PF-04494700,TTP488）, the cell expriment (test) of Azeliragon（PF-04494700,TTP488）, the in vivo, in vitro and clinical trial test of Azeliragon（PF-04494700,TTP488）, the EC50, IC50,and affinity,of Azeliragon（PF-04494700,TTP488）, Please contact DC Chemicals. |
